Kallergis Eleftherios M, Manios Emmanuel G, Kanoupakis Emmanuel M, Schiza Sophia E, Mavrakis Hercules E, Klapsinos Nikolaos K, Vardas Panos E
Department of Cardiology, University Hospital of Heraklion, 71000, Voutes, Heraklion-Crete, Greece.
Chest. 2005 Jun;127(6):2057-63. doi: 10.1378/chest.127.6.2057.
Although inhaled beta2-agonists are in widespread use, several reports question their potential arrhythmogenic effects. The purpose of this study was to evaluate the cardiac electrophysiologic effects of a single, regular dose of an inhaled beta2-agonist in humans.
Prospective study.
Tertiary referral center.
Six patients with bronchial asthma and 12 patients with mild COPD.
All patients underwent an electrophysiologic study before and after the administration of salbutamol solution (5 mg in a single dose).
Sinus cycle length, sinus node recovery time (SNRT), interval from the earliest reproducible rapid deflection of the atrial electrogram in the His bundle recording to the onset of the His deflection (AH), interval from the His deflection to the onset of ventricular depolarization (HV), Wenckebach cycle length (WCL), atrial effective refractory period (AERP), and ventricular effective refractory period (VERP) were evaluated just before and 30 min after the scheduled intervention. Salbutamol, a selective beta2-agonist, administered by nebulizer had significant electrophysiologic effects on the atrium, nodes, and ventricle. The AH length decreased from 86.1 +/- 19.5 ms at baseline to 78.8 +/- 18.4 ms (p < 0.001), and the WCL decreased from 354.4 +/- 44.2 to 336.6 +/- 41.7 ms (p = 0.001). Salbutamol significantly decreased the AERP and VERP too while leaving the HV unchanged. Additionally, inhaled salbutamol increased heart rate (from 75.5 +/- 12.8 beats/min at baseline to 93.1 +/- 16 beats/min, p < 0.001) and shortened the SNRT (from 1,073.5 +/- 178.7 to 925.2 +/- 204.9 ms, p = 0.001).
Inhaled salbutamol results in significant changes of cardiac electrophysiologic properties. Salbutamol enhances atrioventricular (AV) nodal conduction and decreases AV nodal, atrial, and ventricular refractoriness in addition to its positive chronotropic effects. These alterations could contribute to the generation of spontaneous arrhythmias.
尽管吸入性β2受体激动剂被广泛使用,但有几份报告对其潜在的致心律失常作用提出了质疑。本研究的目的是评估单次常规剂量吸入性β2受体激动剂对人体心脏电生理的影响。
前瞻性研究。
三级转诊中心。
6例支气管哮喘患者和12例轻度慢性阻塞性肺疾病(COPD)患者。
所有患者在给予沙丁胺醇溶液(单次剂量5mg)前后均接受了电生理研究。
在预定干预前及干预后30分钟,评估窦性周期长度、窦房结恢复时间(SNRT)、希氏束记录中最早可重复的心房电图快速偏转至希氏波起始的间期(AH)、希氏波至心室去极化起始的间期(HV)、文氏周期长度(WCL)、心房有效不应期(AERP)和心室有效不应期(VERP)。通过雾化器给药的选择性β2受体激动剂沙丁胺醇对心房、节点和心室有显著的电生理作用。AH长度从基线时的86.1±19.5毫秒降至干预后的78.8±18.4毫秒(p<0.001),WCL从354.4±44.2降至336.6±41.7毫秒(p = 0.001)。沙丁胺醇在使HV不变的同时,也显著降低了AERP和VERP。此外,吸入沙丁胺醇可使心率增加(从基线时的75.5±12.8次/分钟增至93.1±16次/分钟,p<0.001),并缩短SNRT(从1073.5±178.7降至925.2±204.9毫秒,p = 0.001)。
吸入沙丁胺醇会导致心脏电生理特性发生显著变化。除了其正性变时作用外,沙丁胺醇还增强房室(AV)结传导,降低AV结、心房和心室的不应期。这些改变可能有助于引发自发性心律失常。